Evidence map›Paper›PMID 41838306›Full record

ArticleDiscover oncology2026

Identified BIRC5 and HDAC1 as novel diagnostic biomarkers linked to centrosome-immune crosstalk for cutaneous squamous cell carcinoma via machine learning-based multi-omics analysis.

Yaqi Fan, Chi Zhang, Yuanjing Zhang, Ruixue Chang, Jiajia Xie, Faxing Jiang, Siping Zhang, Jun Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaqi FanDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Chi ZhangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Yuanjing ZhangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Ruixue ChangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Jiajia XieDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Faxing JiangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Siping ZhangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China.
Jun TangDepartment of Dermatology, The First Affiliated Hospital of University of Science and Technology of China, No.17, Lujiang Street, Luyang District, Hefei, 230001, Anhui Province, China. tangjun0212@ustc.edu.cn.

Funding

the National Natural Science Foundation of China 82303737
6 · The paper itself

Abstract

backgroundCutaneous squamous cell carcinoma (cSCC) is a common skin malignancy, in which immune dysregulation plays a pivotal role in driving disease progression and therapy resistance. Centrosomal amplification (CA), a marker of genomic instability, promotes cancer development by disrupting essential biological processes, including cell division, immune activation, antigen presentation, and cytokine signaling. Therefore, exploring the interaction between centrosomal alterations and immune regulation may reveal new therapeutic targets, thereby improving diagnostic and treatment approaches for cSCC.

methodsCentrosomal and immune-related biomarkers for cSCC were identified by screening public databases using 101 combinatorial models derived from 10 machine learning algorithms. Subsequent RT-qPCR validation was complemented by artificial neural network (ANN) analysis to evaluate the diagnostic potential of these candidate biomarkers. The underlying mechanisms of the identified biomarkers were further explored through enrichment analysis, immune infiltration profiling, and single-cell RNA sequencing.

resultsTwo biomarkers, BIRC5 and HDAC1, were identified. Both are primarily expressed in epithelial cells and demonstrate significant diagnostic potential for cSCC. These molecules are closely associated with the cell cycle and immune checkpoints, particularly CD276. Single-cell RNA sequencing revealed eight distinct epithelial cell types, with BIRC5 and HDAC1 exhibiting the highest expression levels, suggesting their involvement in cSCC development by affecting epithelial cell function during tumor initiation and progression.

conclusionThis study identifies BIRC5 and HDAC1 as important biomarkers that facilitate centrosome-immune communication, offering promising targets for accurate diagnosis and treatment strategies in cSCC management.

Indexed as

CentrosomalCSCCImmuneSingle-cell RNA sequencing

Identifiers

PMID41838306
PMCPMC13103176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.